According to a major international study, Switzerland has once again fallen behind other European countries in terms of access to new innovative medicines – from sixth to seventh place. Particularly worrying is the fact that, compared to Germany, only around half as many new innovative medicines are reimbursed as standard via the specialty list.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- DERMATOLOGIE PRAXIS
Related Topics
You May Also Like
- Rare pulmonary syndromes
Yellow nail and Swyer-James syndrome
- Vaccinations against viral respiratory infections
Influenza, Covid-19 and RSV – Update 2025
- GLP1-RA therapy
Improvement in either weight or HbA1c – but never both
- Suicide
Dealing with trauma after suicide loss: What do bereaved people experience as effective?
- COPD exacerbations
Fast therapy initiation is not much better than expected
- Lung cancer with EGFR mutation
New perspectives in first-line therapy
- Galenic systems
Advantages of topical pharmacotherapy – Update 2025
- Collagenoses